key: cord-0761389-15bvcgzu authors: Echarte-Morales, Julio; Minguito-Carazo, Carlos; del Castillo García, Samuel; Borrego-Rodríguez, Javier; Rodríguez-Santamarta, Miguel; Sánchez-Muñoz, Enrique; García, Rubén Bergel; Maniega, Clea González; Prieto-González, Silvia; Suarez, Paula Menéndez; Tundidor-Sanz, Elena; Benito-González, Tomás; Fernández-Vázquez, Felipe title: Effect of Hydroxychloroquine, azithromycin and Lopinavir/ritonavir on the QT corrected interval in patients with COVID-19: Effect of triple therapy on QTc in patients with COVID-19. date: 2020-11-28 journal: J Electrocardiol DOI: 10.1016/j.jelectrocard.2020.11.012 sha: 0be0a78b0b809ef2bd14ae01dca4dbb9251cb9ee doc_id: 761389 cord_uid: 15bvcgzu Background: Administration of Hydroxychloroquine and Azithromycin in patients with coronavirus disease 2019 (COVID-19) prolongs QTc corrected interval (QTc). The effect and safety of Lopinavir/Ritonavir in combination with these therapies have seldom been studied. Objectives: Our aim was to evaluate changes in QTc in patients receiving double (Hydroxychloroquine + Azithromycin) and triple therapy (Hydroxychloroquine + Azithromycin + Lopinavir/Ritonavir) to treat COVID-19. Secondary outcome was the incidence of in-hospital all-cause mortality. Methods: Patients under treatment with double (DT) and triple therapy (TT) for COVID-19 were consecutively included in this prospective observational study. Serial in-hospital electrocardiograms were performed to measure QTc at baseline and during therapy. Results: 168 patients (±66.2 years old) were included: 32.1% received DT and 67.9% received TT. The mean baseline QTc was 410.33 ms. Patients under DT and TT prolonged QTc interval respect baseline values (p < 0.001), without significant differences between both therapy groups (p = 0.748). Overall, 33 patients (19.6%) had a peak QTc and/or an increase QTc 60 ms from baseline, with a higher prevalence among those with hypokalemia (p = 0.003). All-cause mortality was similar between both strategy groups (p = 0.093) and high risk QTc prolongation was no related to clinical events in this series. Conclusions: DT and TT prolong the QTc in patients with COVID-19. Addition of Lopinavir/Ritonavir on top of Hydroxychloroquine and Azithromycin did not increase QTc compared to DT. Since its emergence in China in the late 2019, severe acute respiratory coronavirus-2, the virus responsible for the coronavirus disease 2019 (COVID- 19) has spread around the globe. Some studies have shown an increased rate of cardiac ventricular arrhythmias (VA) and sudden cardiac death (SCD) among these patients [1, 2] . The efficacy of current pharmacological therapies to treat this infection has not been yet demonstrated in large-scale studies [3, 4] . Despite the lack of evidence, Lopinavir/ritonavir, Hydroxychloroquine and Azithromycin have been commonly used at a first line empiric therapy in most centers. All these drugs have been associated with a prolongation of QT corrected interval (QTc) as a non-uncommon side effect, which has raised concern about the risk of VA, specifically torsade de pointes, and SCD [5, 6] . Recent studies performed during the pandemic period have analyzed the effect on the QTc of Azithromycin, Hydroxychloroquine and the combination of both drugs [7, 8] . Patients with non-confirmed test for COVID-19, those with no electrocardiogram (ECG) at baseline and at least one ECG during follow up and those who did not receive at least one dose of either prespecified combined therapy were excluded. The flowchart of the study is presented in Figure 1 . The choice of treatment in each patient was based on physician´s criteria and local guidelines. COVID-19 diagnosis was confirmed with polymerase chain reaction (PCR) test in all patients. Serum samples were obtained at admission to analyze biochemical parameters, including acute phase reactants. Lowest serum potassium documented during hospitalization was collected. CURB 65 score (confusion, urea > 7 mmol/L, respiratory rate ≥ 30 bpm, blood pressure < 90/60 mmHg, age > 65 years) was calculated at admission [9] . The standard prescription of the 3 analyzed drugs were: 400 mg of Hydroxychloroquine twice on day 1 and 200 mg twice a day on days 2 to 5; 500mg of Azithromycin once on day 1 and 250 mg daily for 4 days more; and 200/50mg of Lopinavir/Ritonavir twice a day during two weeks. Patients were classified in two treatment groups: Double therapy (DT) with Hydroxychloroquine and Azithromycin, or Triple therapy (TT) adding by at least one of two experienced cardiologists (C. M. C. and J.E.M) to calculate QTc using Bazzet´s formula on lead II and V5 [11] . When ECG complex was not optimal in these leads, I and aVL were used as an alternative. For patients with a wide QRS from either ventricular pacing or left/right bundle branch block the excess correction method was used [12] . In patients with atrial fibrillation (AF), QTc was estimated as the mean of 3-5 beats. Prolonged QTc was defined as ≥ 450 ms in males and ≥ 470 ms in females [13] . The longest QTc measured after COVID-19 drugs were started was considered as peak QTc during admission. Patients with a peak QTc ≥ 500ms and those with an increase in the QTc ≥ 60ms from baseline values were considered at high risk for VA [14] . Discontinuation of any of analyzed COVID-19 therapies was decided by referral physician taking into account the presence of high risk QTc pattern, the severity of underlying pneumonia and the potential alternatives drugs. The primary aim of the study was to evaluate changes in QTc in patients receiving DT vs TT to treat COVID-19. Secondary outcome was the incidence of in-hospital all-cause mortality. All data were collected using standardized report forms including demographic features, medical history, baseline clinical characteristics, biochemical and ECG findings, medical treatment during admission and in-hospital clinical outcomes. The study was approved by the local Ethics Committee and adhered to the principles outlined in the Declaration of Helsinki. Individual informed consent was obtained from participants. Continuous variables were summarized as mean  standard deviation (SD) or as medians and interquartile range (IQR) and were compared using paired or unpaired Student T tests or the A total of 168 ( 66.2 years old) patients with a diagnosis of COVID-19 infection were enrolled. Baseline characteristics of the included cohort are displayed in Table 1 grouped by the administration of DT (32.1%) or TT (67.9%). Patients under DT had more frequently chronic kidney disease (p=0.007), with higher levels of serum creatinine at admission (p=0.046) and were more commonly on other drugs associated with QTc prolongation (p=0.021). Serum levels of lactate dehydrogenase were higher in the group under TT (p=0.014). Most patients were in sinus rhythm at admission and AF was present in 15 (8.9%) patients. The mean baseline QTc was 410.3  33.9 ms and 10.7% patients presented prolonged QTc before COVID-19 therapy was started ( Table 2) . Three (1,8%) patients had a QTc ≥ 500 ms at baseline. Indication of combined therapy in these cases was done due to severe clinical status with no reliable therapeutic alternatives. No differences in baseline ECG features were found among patients who received either DT or TT. During in-hospital ECG monitoring, QTc did significantly increased in both therapy arms compared to baseline (DT: were considered at high risk of VA due to an increase of QTc 60 ms or a QTc. In 6 (3.6%) patients' medication was discontinued due to QTc prolongation ( Figure 3 ). During a median follow up of 23 [13.5 -30.0] days, 16 (9.6 %) patients died, with no differences between both treatment arms (13.2% vs 8.0%, p =0.296). In all these patients, worsening of COVID-19 pneumonia was considered the cause of death. Survival free of death from any cause was similar in both therapy groups (p=0.093, Figure 4A ) and among patients with or without high risk QTc prolongation (p= 0.322, Figure 4B ). Journal Pre-proof The main findings of our study were: 1) the combination of HCA and Azithromycin with or without Lopinavir/Ritonavir increased QTc; 2) the addition of Lopinavir/Ritonavir to Hydroxychloroquine and Azithromycin was not related to a significant increase of the peak QTc compared to stand-alone DT; 3) low levels of serum potassium were independently related to the incidence of high risk prolonged QTc peak; 4) the prolongation of QTc was not associated to all-cause mortality in our series. Given the lack of data regarding effectiveness of dedicated drugs to treat COVID-19, empiric combination of diverse medications has been widely used in these cases. Among them, Hydroxychloroquine, Azithromycin, and Lopinavir/Ritonavir are commonly administered in subjects requiring hospitalization due to COVID-19 pneumonia [3, 4] . Although recent observational reports have shown neutral or even negative outcomes with some of these combined therapies, diverse randomized controlled trials are currently being carried out in order to get a definite answer to their effectiveness. Hydroxychloroquine is believed to act on the entry and post-entry stages of COVID-19 and blocks the hERG potassium channel, therefore potentially prolonging QTc [15] . Azithromycin is a macrolide frequently prescribed to treat a wide spectrum of infections. The association between Azithromycin and prolongation of QTc has been also published, despite it appears to have a lower interaction with the hERG channel [16] . shown to be effective in patients with COVID-19 in vitro and in animal models [17] [18] [19] . This antiretroviral drug also inhibits the hERG although reported interaction with QTc shows conflicting results [20] . Therefore, these three drugs inhibit the hERG channel, although the grade of affinity of each of them to this receptor has not been already fully Drug-induced QTc prolongation is an important substrate for VA, although the incidence of potentially life-threatening polymorphic VA in daily practice seems to be low [24] . Bessière et al. found a significant increase in QTc in patients treated with Hydroxychloroquine that was statistically higher in those with DT compared to monotherapy. In this small series of patients admitted in the critical care unit, no polymorphic VA or SCD was documented [25] . Similar results were reported in two larger cohorts of hospitalized patients with COVID-19 pneumonia [7, 8] . Given reported very low incidence of VA and the risk of contagious in the setting of COVID-19, serial ECG could be considered if continuous ECG monitoring is not available [10] . In our cohort, patients under DT and TT prolonged QTc compared to baseline values. Nevertheless, patients with TT did not show a greater increase in the QTc compared to those on DT. The interaction between Lopinavir/Ritonavir and QTc has not been completely clarify yet. Although fairly reported in literature, the incidence of prolonged QTc seems to be very low in patients on monotherapy [3] . In this regard, Charbit et al. From a clinical perspective, although the use of these medications resulted in significant QTc prolongation, the need to withdraw any of these drugs was very infrequent. Nevertheless, given the exceptional circumstances of COVID-19, including oversaturated healthcare resources, wide heterogeneity of physician specialists taking care of these patients, the severe morbidity and mortality of hospitalized patients and the lack of evidence-supported dedicated therapies, this rate might be higher in a more "normalized" setting. No differences in all-cause mortality were reported, similarly to previous studies. As priorly suggested by Giudicessi et al., we considered patients with a peak QTc ≥ 500 ms and/or an increase of QTc ≥ 60 ms from baseline to be at high risk of VA or SCD [10] . . Overall, 19.6% patients fulfilled these criteria of high risk in our cohort. Nevertheless, this pattern was not related to clinical outcomes in our series. In multivariate analysis, hypokalemia was significantly associated to a 4-fold likehood to present this high risk This study has several limitations inherent to its observational nature. First, sample size is small, and patients were enrolled in one single center so that our results should be interpreted with caution. Second, given non-randomized controlled design both therapy arms presented some significant differences in baseline features which could have influenced these findings. Third, the absence of a control cohort of patients with COVID-19 that were not treated with any of these medications should be taking into account when considering the findings of this report. Four, due to unavailability of continuous ECG monitoring in conventional wards, accurate incidence of VA and arrhythmic SCD could not be documented. Patients who received DT experienced QTc prolongation and, according to results in this series, Lopinavir/Ritonavir could be safely added to DT in patients with COVID-19 without a significant increase in QTc compared to DT. There were no differences in mortality between both strategies. Despite the increase in QTc in most patients, discontinuation of treatment was seldomly performed. What is known? Hydroxychloroquine and Azithromycin prolong QTc in patients with COVID-19, prompting ECG monitoring due to increased risk of ventricular arrythmias. What is the new? The impact of Lopinavir/Ritonavir in addition to Hydroxychloroquine and Azithromycin on QTc has not been studied previously. In our series, triple therapy did not further prolong QTc interval compared to double therapy. Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease Association of Cardiac Injury with Mortality in Hospitalized Patients with COVID-19 in Wuhan, China A trial of lopinavirritonavir in adults hospitalized with severe covid-19 Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Assessing proarrhythmic potential of drugs when optimal studies are infeasible Prevention of torsade de pointes in hospital settings: A scientific statement from the American heart association and the American college of cardiology foundation Concomitant Azithromycin among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19) The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection Defining community acquired pneumonia severity on presentation to hospital: An international derivation and validation study Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study) Issues in QT interval measurement Institution-wide QT alert system identifies patients with a high risk of mortality In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Risk evaluation of azithromycininduced QT prolongation in real-world practice Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERSCoV infection in a nonhuman primate model of common marmoset Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): Study protocol for a randomized controlled trial Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection Azithromycin Causes a Novel Proarrhythmic Syndrome Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation: Importance of use-dependent effects on refractoriness Drug-Induced Prolongation of the QT Interval Assessment of QT Intervals in a Case Series of Patients with Coronavirus Disease 2019 (COVID-19) Infection Treated with Hydroxychloroquine Alone or in Combination with Azithromycin in an Intensive Care Unit